journal
https://read.qxmd.com/read/38734491/gastrointestinal-toxicity-of-antibody-drug-conjugates-adcs-in-metastatic-breast-cancer-a-pooled-analysis
#1
REVIEW
Rebecca Pedersini, Martina Buffoni, Fausto Petrelli, Antonio Ghidini, Pierluigi di Mauro, Vito Amoroso, Maria Chiara Parati, Lara Laini, Deborah Cosentini, Greta Schivardi, Giuseppe Ippolito, Alfredo Berruti, Marta Laganà
Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with these drugs in clinical trials, a pooled analysis evaluating gastrointestinal adverse events (AEs) in patients with MBC treated with ADCs in clinical trials was performed. PubMed, Embase, and the Cochrane Library were searched from inception until May 2023 for phase II and III clinical trials reporting frequency and severity of gastrointestinal AEs during treatment with ADCs...
April 8, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38729822/female-sexual-function-index-adaptation-for-breast-cancer-patients-fsfi-bc-brazilian-portuguese-translation-and-cultural-adaptation
#2
JOURNAL ARTICLE
Ana Cláudia Neves Gonçalves, Renata Bites Amorim, Bianca de Souza Domingues, Júlia Vieira Araújo Sousa, Daniela Francescato Veiga
BACKGROUND: The assessment of female sexual function after diagnosis and treatment of breast cancer is relevant, as cancer can negatively affect sexuality and, therefore, quality of life. Instruments assessing female sexuality can be useful in clinical practice. However, there are few validated instruments available for this purpose. This study aimed to translate the Female Sexual Function Index Adaptation for Breast Cancer Patients (FSFI-BC) into Brazilian Portuguese and culturally adapt it for use in Brazil...
April 8, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38719678/implementing-indicators-and-trajectories-of-return-to-work-after-breast-cancer-diagnosis-a-mixed-methods-study-using-the-french-national-healthcare-insurance-database-and-stakeholder-consultation
#3
JOURNAL ARTICLE
Romain Varnier, Aurélie Moskal, Céline Bodelet, Julien Péron, Marion Lamort-Bouché, Jean-Baptiste Fassier, Alexandra L Dima, Marie Viprey
PURPOSE: Return to work (RTW) is important for quality of life after breast cancer but its analysis at the population-level remains limited in France. This study aimed to implement Electronic Healthcare Data (EHD)-based indicators and trajectories to measure RTW after breast cancer diagnosis, and to examine stakeholders' perspectives regarding these indicators. METHODS: We followed a mixed-methods approach that consisted of (i) implementing RTW indicators and identifying clusters of trajectories using state sequence analysis with data from a representative sample of the French National Health Data System and (ii) exploring, through qualitative focus group and interviews, stakeholders' perceptions on the interpretation, limitations, and utility of these indicators...
April 7, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38729821/effectiveness-and-safety-of-pyrotinib-based-therapy-in-the-treatment-of-her2-positive-breast-cancer-patients-with-brain-metastases-a-multicenter-real-world-study
#4
JOURNAL ARTICLE
Jie Huang, Shujuan Sun, Qiaorui Tan, Fangchao Zheng, Dongdong Zhou, Xiaochu Man, Yu Hu, Wenhuan Li, Lihua Song, Baoxuan Zhang, Liang Xu, Xinzhao Wang, Xuemei Xie, Huihui Li
BACKGROUND: Approximately 30% to 50% of patients with human epidermal growth factor receptor 2-positive metastatic breast cancer develop brain metastasis (BMs). Pyrotinib has shown promising efficacy in these patients. However, real-world evidence supporting its use is scarce. Therefore, we evaluate the efficacy and safety of pyrotinib-based regimens in the real world. MATERIALS AND METHODS: We enrolled patients with BMs from various healthcare facilities in China's Shandong region and used an updated breast-graded prognostic assessment (breast-GPA) to predict survival outcomes...
April 6, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38670860/survival-outcomes-in-thyroid-cancer-patients-with-co-occurring-breast-cancer-evidence-of-mortality-risk-attenuation
#5
JOURNAL ARTICLE
Matheus Wohlfahrt Baumgarten, Iuri Martin Goemann, Rafael Selbach Scheffel, Ana Luiza Maia
BACKGROUND: Previous studies have reported a strong correlation between breast cancer (BC) and thyroid cancer (TC) incidence. However, the clinical and oncological impact of these associations are not yet fully understood. Here, we aimed to explore the differences in clinicopathological characteristics between TC patients with and without BC, and the effect of a history of positive BC on TC survival. METHODS: We retrospectively compared the clinical characteristics and survival rates of patients with TC alone and those with TC and BC in a primary cohort at our institution and in a second cohort using the Surveillance, Epidemiology, and End Results (SEER) database...
April 6, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38670861/screening-mammography-for-males-with-elevated-breast-cancer-risk-mutation-carriers-and-gynecomastia
#6
JOURNAL ARTICLE
Ahuva Grubstein, Marva Dahan, Wael Jomar, Tal Friehmann, Shlomit Tamir, Tzippy Shochat, Eli Atar, Tanir M Allweis
INTRODUCTION: The recommendations for annual mammography for male carriers with gynecomastia are controversial. This study investigated the potential link between gynecomastia and breast cancer in male carriers. PATIENTS AND METHODS: The database of a tertiary medical center was retrospectively searched for all male patients who underwent at least 1 digital mammography study from 2016 to 2023. Known carriers of a pathogenic variant in a high-risk breast-cancer gene were identified...
April 4, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38653647/the-introduction-of-magtrace%C3%A2-lymphatic-tracer-for-axillary-sentinel-node-biopsy-for-breast-cancer-in-a-rural-scottish-district-general-hospital-initial-experience-perspectives-outcomes-and-learning-curves
#7
JOURNAL ARTICLE
Chia Yew Kong, Jacob Williams, Niroshini Hemadasa, Dermot Murphy, Maria Bews-Hair
BACKGROUND: Magtrace is a supraparamagnetic iron lymphatic tracer that has had increasing use in sentinel node biopsy (SNB) for breast cancer and has theoretical logistical benefits in centres where nanocolloid use may be associated with such issues. We describe our initial experience with the introduction of Magtrace into our routine practice by dual localisation with nanocolloid, comparing performance, and concordance. MATERIALS AND METHODS: This was prospective study of the first patients undergoing axillary SNB using Magtrace in a single centre...
March 30, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38627193/existing-psychiatric-diagnoses-among-breast-cancer-patients-interact-with-outcomes-after-autologous-and-implant-based-bilateral-breast-reconstruction-a-propensity-score-matched-analysis
#8
JOURNAL ARTICLE
George S Corpuz, Dylan K Kim, Isaac E Kim, Christine H Rohde
BACKGROUND: Breast reconstruction is an integral postoncologic procedure that has been associated with improved mental health and psychological outcomes. The possible interaction between existing psychiatric diagnoses hospital courses and postoperative complications warrants further exploration. METHODS: Bilateral breast reconstruction patients were identified from the 2016 to 2018 Healthcare Cost and Utilization Project-National Inpatient Sample (HCUP - NIS). Number and type of psychiatric diagnoses within the cohort were then evaluated using a host of ICD-10 codes...
March 24, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38627192/development-of-an-ultrasound-based-nomogram-for-predicting-pathologic-complete-response-and-axillary-response-in-node-positive-patients-with-triple-negative-breast-cancer
#9
JOURNAL ARTICLE
Manqi Zhang, Hailing Zha, Jiazhen Pan, Xiaoan Liu, Min Zong, Liwen Du, Yu Du
BACKGROUND: The accurate prediction of pathological complete response (pCR) in the breast and axillary lymph nodes (ALN) before neoadjuvant chemotherapy (NAC) is of utmost importance for the development of treatment strategies. We aim to construct a nomogram on ultrasound (US) and clinical-pathologic factors to predict breast and ALN pCR in node-positive triple-negative breast cancers (TNBCs). METHODS: Patients identified with TNBCs from institution 1 (n = 328) were used for training cohort and those from institution 2 (n = 192) were for validation cohort...
March 23, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38609794/comparison-of-clinical-breast-exam-to-breast-mri-surveillance-in-patients-following-nipple-sparing-mastectomy
#10
JOURNAL ARTICLE
Christina Weed, Ton Wang, Srivarshini C Mohan, Xuanji Wang, Joshua Tseng, Theodore Hu, Jutla Jaswinder, Marissa K Boyle, Farin Amersi, Armando Giuliano, Alice Chung
BACKGROUND: Nipple sparing mastectomy (NSM) is increasingly being performed for patients with breast cancer. However, optimal postoperative surveillance has not been defined. METHODS: A prospectively maintained database identified patients with in-situ and invasive cancer who underwent NSM between 2007-2021. Clinical data on postoperative breast surveillance and interventions were collected. Patients who had MRI surveillance versus clinical breast exam (CBE) alone were compared with respect to tumor characteristics, recurrence, and survival...
March 20, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38641470/the-fgfr2-variant-rs13387042-is-associated-with-breast-cancer-risk-a-meta-analysis-and-systematic-review
#11
JOURNAL ARTICLE
Weining Pan, Hui Cheng, Juan Zhang, Zijie Yang, Mengbo Lin
OBJECTIVE: The association of FGFR2-rs13387042 polymorphism with breast cancer (BC) susceptibility in women remains inconclusive due to varying reports. In this study, we conducted a meta-analysis to explore the relationship between FGFR2-rs13387042 polymorphism and susceptibility to BC. METHODS: Relevant literature were acquired through searches across multiple databases. Odds ratio (OR) values were pooled to assess the risk of BC for different alleles and genotypes...
March 15, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38616444/plasma-thioredoxin-reductase-as-a-potential-diagnostic-biomarker-for-breast-cancer
#12
JOURNAL ARTICLE
Yixuan Hu, Yinxing Zhu, Junfeng Shi, Xiaowei Wei, Cuiju Tang, Xiaoxiang Guan, Wenwen Zhang
BACKGROUND: Early diagnosis of breast cancer is critical to the treatment and prognosis of breast cancer patients. Our aim is to explore more practical and effective diagnostic methods to facilitate early treatment and improve prognosis for breast cancer patients. MATERIALS AND METHODS: The Mann-Whitney U test, receiver operating characteristic curve, Youden index, Chi-square test, and Fisher's exact test were used to determine whether plasma thioredoxin reductase (TrxR) could be used for the clinical diagnosis of breast cancer...
March 15, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38614852/hypofractionation-for-regional-nodal-irradiation-in-breast-cancer-best-of-both-the-worlds
#13
REVIEW
Budhi Singh Yadav, Treshita Dey
Locoregional radiotherapy play an important role in controlling the disease after surgery in patients with breast cancer. Radiotherapy schedules vary from conventional fraction to hypofractionation. The purpose of this review is to get an insight into the data on regional nodal irradiation (RNI) with hypofractionation in patients with breast cancer. This systematic review was constructed in accordance with Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) framework. Electronic databases such as PubMed, Cochrane and EMBASE were searched from January 1, 2023 to March 31, 2023 to identify studies published in English language on hypofractionated RNI in post mastectomy patients...
March 14, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38616443/systemic-therapy-advances-for-her2-positive-and-triple-negative-breast-cancer-what-the-surgeon-needs-to-know
#14
REVIEW
Stephanie Downs-Canner, Anna Weiss
Neoadjuvant systemic therapy (NST) was initially reserved for unresectable patients however it has been increasingly used to facilitate breast conservation, downstage the axilla, and inform adjuvant therapy decisions based on response. For patients with HER2+ and triple-negative breast cancer (TNBC), clinical trials have resulted in the ability to individualize treatment regimens. For HER2+ breast cancer, de-escalation of neoadjuvant regimens to minimize cytotoxic chemotherapy and de-escalation or escalation of adjuvant regimens based on response have been effective...
March 13, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38580573/nomogram-based-on-us-and-clinicopathologic-characteristics-axillary-nodal-evaluation-following-neoadjuvant-chemotherapy-in-patients-with-node-positive-breast-cancer
#15
JOURNAL ARTICLE
Jia-Xin Huang, Yi-Jie Chen, Xue-Yan Wang, Jia-Hui Huang, Ke-Hong Gan, Li-Na Tang, Xiao-Qing Pei
BACKGROUND: To develop a convenient modality to predict axillary response to neoadjuvant chemotherapy (NAC) in breast cancer patients. MATERIALS AND METHODS: In this multi-center study, a total of 1019 breast cancer patients with biopsy-proven positive lymph node (LN) receiving NAC were randomly assigned to the training and validation groups at a ratio of 7:3. Clinicopathologic and ultrasound (US) characteristics of both primary tumors and LNs were used to develop corresponding prediction models, and a nomogram integrating clinicopathologic and US predictors was generated to predict the axillary response to NAC...
March 13, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38555225/combination-of-dce-mri-and-nme-dwi-via-deep-neural-network-for-predicting-breast-cancer-molecular-subtypes
#16
JOURNAL ARTICLE
Zhi-Chang Ba, Hong-Xia Zhang, Ao-Yu Liu, Xin-Xiang Zhou, Lu Liu, Xin-Yi Wang, Abiyasi Nanding, Xi-Qiao Sang, Zi-Xiang Kuai
BACKGROUND: To explore whether the combination of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) and nonmono-exponential (NME) model-based diffusion-weighted imaging (DWI) via deep neural network (DNN) can improve the prediction of breast cancer molecular subtypes compared to either imaging technique used alone. PATIENTS AND METHODS: This prospective study examined 480 breast cancers in 475 patients undergoing DCE-MRI and NME-DWI at 3.0 T. Breast cancers were classified as follows: human epidermal growth factor receptor 2 enriched (HER2-enriched), luminal A, luminal B (HER2-), luminal B (HER2+), and triple-negative subtypes...
March 13, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38582616/is-immediate-breast-reconstruction-with-a-latissimus-dorsi-myocutaneous-flap-safe-for-starting-adjuvant-chemotherapy-in-patients-with-breast-cancer
#17
JOURNAL ARTICLE
Gabriel Salum D'Alessandro, Alexandre Mendonça Munhoz, Fabiana Midori Takeuchi, Alejandro Povedano, João Carlos Sampaio Goes
INTRODUCTION: Immediate breast reconstruction following mastectomy reduces perceptions of mutilation and femininity issues in oncological patients, but surgical complications should not delay chemotherapy. This study evaluated postsurgical complications in patients who underwent radical breast surgery followed by immediate reconstruction with latissimus dorsi myocutaneous flaps and silicone implants, along with resulting impacts in delaying chemotherapy. MATERIALS AND METHODS: This retrospective study utilized a prospectively maintained database...
March 10, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38670862/the-efficiency-and-toxicity-of-anlotinib-in-combination-with-docetaxel-followed-by-epirubicin-and-cyclophosphamide-regimen-as-neoadjuvant-treatment-in-iib-to-iiia-triple-negative-breast-cancer-a-single-arm-multicenter-open-label-phase-ii-study
#18
EDITORIAL
Xi Chen, Xinyu Wei, Peizhuo Yao, Yanbin Liu, Haitao Guan, Huafeng Kang, Di Liu, Yan Diao, Xiaobin Ma, Weili Min, Changyou Shan, Yang Zhao, Fang Zhao, Yuanyuan Chen, Dong Xiao, Qing She, Youhuai Liu, Yinbin Zhang, Shuqun Zhang
BACKGROUND: The combination of neoadjuvant chemotherapy and anti-angiogenesis therapy for patients with triple-negative breast cancer (TNBC) remains inadequately supported by evidence. We conducted a single-arm, open-label, multicenter, phase II trial to evaluate the efficacy and toxicity of anlotinib plus epirubicin and cyclophosphamide followed by paclitaxel in patients with IIB to IIIA stage TNBC. METHODS: Newly diagnosed patients received epirubicin at 90 mg/m2 and cyclophosphamide at 600 mg/m2 followed by docetaxel at 100 mg/m2 (21 days per cycle; total of 4 cycles), along with oral anlotinib (12 mg qd, d1-14; 21 days per cycle; total of 4 cycles)...
March 8, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38582617/the-role-of-immunotherapy-in-triple-negative-breast-cancer-tnbc
#19
REVIEW
Elena Michaels, Nan Chen, Rita Nanda
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype, generally associated with a high risk of recurrence and poor prognosis. Our understanding of the heterogeneity of TNBC has increased over the past decade, and with it a recognition that some TNBCs are immunogenically active. This finding has led to the investigation of immunotherapy-based approaches for treatment of both early and advanced-stage TNBC. In this review, we provide an overview of the biologic rationale for immunotherapy use in TNBC, and review data from seminal trials which have culminated in the approval of immunotherapy for both early and advanced TNBC...
March 6, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38553373/expression-and-clinical-significance-of-nudcd1-pi3k-akt-mtor-signaling-pathway-related-molecules-and-immune-infiltration-in-breast-cancer
#20
JOURNAL ARTICLE
Wei Wen, Yuehua Li, Xi Cao, Yanyan Li, Ziyi Liu, Zhuoqi Tang, Liming Xie, Rongfang He
BACKGROUND: NUDCD1 (NudC Domain Containing 1) performs an essential function in biological processes such as cell progression, migration, cell cycle, and intracellular material transport. Many solid tumors express it highly, which is a prospective biomarker and therapeutic approach. However, the expression and clinical importance of NUDCD1 across breast cancer is unclear. METHODS: The expressions of NUDCD1 in breast cancers and normal breast tissues were studied utilizing the TIMER database and immunohistochemical analysis...
March 6, 2024: Clinical Breast Cancer
journal
journal
34827
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.